Annual EBITDA
-$341.35 M
-$61.44 M-21.95%
December 31, 2023
Summary
- As of February 8, 2025, SWTX annual EBITDA is -$341.35 million, with the most recent change of -$61.44 million (-21.95%) on December 31, 2023.
- During the last 3 years, SWTX annual EBITDA has fallen by -$295.37 million (-642.46%).
- SWTX annual EBITDA is now -1747.71% below its all-time high of -$18.47 million, reached on December 31, 2018.
Performance
SWTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$57.06 M
-$12.98 M-29.45%
September 30, 2024
Summary
- As of February 8, 2025, SWTX quarterly EBITDA is -$57.06 million, with the most recent change of -$12.98 million (-29.45%) on September 30, 2024.
- Over the past year, SWTX quarterly EBITDA has dropped by -$12.98 million (-29.45%).
- SWTX quarterly EBITDA is now -603.65% below its all-time high of $11.33 million, reached on December 31, 2020.
Performance
SWTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$292.26 M
+$26.45 M+8.30%
September 30, 2024
Summary
- As of February 8, 2025, SWTX TTM EBITDA is -$292.26 million, with the most recent change of +$26.45 million (+8.30%) on September 30, 2024.
- Over the past year, SWTX TTM EBITDA has increased by +$26.45 million (+8.30%).
- SWTX TTM EBITDA is now -5491.41% below its all-time high of -$5.23 million, reached on September 30, 2018.
Performance
SWTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SWTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | -29.4% | +8.3% |
| 3 y3 years | -642.5% | -29.4% | +8.3% |
| 5 y5 years | -1747.7% | -29.4% | +8.3% |
SWTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -97.3% | at low | -29.4% | +41.7% | -69.0% | +18.2% |
| 5 y | 5-year | -642.5% | at low | -603.6% | +41.7% | -535.7% | +18.2% |
| alltime | all time | -1747.7% | at low | -603.6% | +41.7% | -5491.4% | +18.2% |
SpringWorks Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$57.06 M(+29.5%) | -$292.26 M(-8.3%) |
| Jun 2024 | - | -$44.08 M(-52.7%) | -$318.71 M(-10.8%) |
| Mar 2024 | - | -$93.20 M(-4.8%) | -$357.10 M(+4.6%) |
| Dec 2023 | -$341.35 M(+21.9%) | -$97.92 M(+17.3%) | -$341.35 M(+6.1%) |
| Sep 2023 | - | -$83.50 M(+1.3%) | -$321.62 M(+3.9%) |
| Jun 2023 | - | -$82.47 M(+6.5%) | -$309.64 M(+4.6%) |
| Mar 2023 | - | -$77.45 M(-1.0%) | -$295.99 M(+5.7%) |
| Dec 2022 | -$279.91 M(+61.8%) | -$78.20 M(+9.3%) | -$279.91 M(+8.8%) |
| Sep 2022 | - | -$71.53 M(+3.9%) | -$257.36 M(+13.6%) |
| Jun 2022 | - | -$68.82 M(+12.2%) | -$226.61 M(+10.7%) |
| Mar 2022 | - | -$61.36 M(+10.3%) | -$204.69 M(+18.3%) |
| Dec 2021 | -$172.98 M | -$55.65 M(+36.5%) | -$172.98 M(+63.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$40.78 M(-13.1%) | -$106.00 M(+22.2%) |
| Jun 2021 | - | -$46.91 M(+58.2%) | -$86.72 M(+45.6%) |
| Mar 2021 | - | -$29.65 M(-361.7%) | -$59.56 M(+29.6%) |
| Dec 2020 | -$45.98 M(-22.1%) | $11.33 M(-152.7%) | -$45.98 M(-38.4%) |
| Sep 2020 | - | -$21.50 M(+8.9%) | -$74.61 M(+9.1%) |
| Jun 2020 | - | -$19.75 M(+23.0%) | -$68.38 M(+7.8%) |
| Mar 2020 | - | -$16.06 M(-7.2%) | -$63.44 M(+7.4%) |
| Dec 2019 | -$59.05 M(+219.6%) | -$17.31 M(+13.4%) | -$59.05 M(+22.6%) |
| Sep 2019 | - | -$15.27 M(+3.1%) | -$48.18 M(+26.3%) |
| Jun 2019 | - | -$14.81 M(+26.9%) | -$38.14 M(+63.5%) |
| Mar 2019 | - | -$11.67 M(+81.2%) | -$23.33 M(+100.0%) |
| Dec 2018 | -$18.47 M | -$6.44 M(+23.2%) | -$11.67 M(+123.2%) |
| Sep 2018 | - | -$5.23 M | -$5.23 M |
FAQ
- What is SpringWorks Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics annual EBITDA year-on-year change?
- What is SpringWorks Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics quarterly EBITDA year-on-year change?
- What is SpringWorks Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics TTM EBITDA year-on-year change?
What is SpringWorks Therapeutics annual EBITDA?
The current annual EBITDA of SWTX is -$341.35 M
What is the all time high annual EBITDA for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high annual EBITDA is -$18.47 M
What is SpringWorks Therapeutics annual EBITDA year-on-year change?
Over the past year, SWTX annual EBITDA has changed by -$61.44 M (-21.95%)
What is SpringWorks Therapeutics quarterly EBITDA?
The current quarterly EBITDA of SWTX is -$57.06 M
What is the all time high quarterly EBITDA for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high quarterly EBITDA is $11.33 M
What is SpringWorks Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SWTX quarterly EBITDA has changed by -$12.98 M (-29.45%)
What is SpringWorks Therapeutics TTM EBITDA?
The current TTM EBITDA of SWTX is -$292.26 M
What is the all time high TTM EBITDA for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high TTM EBITDA is -$5.23 M
What is SpringWorks Therapeutics TTM EBITDA year-on-year change?
Over the past year, SWTX TTM EBITDA has changed by +$26.45 M (+8.30%)